On Friday, C4 Therapeutics Inc (NASDAQ: CCCC) opened lower -8.69% from the last session, before settling in for the closing price of $4.72. Price fluctuations for CCCC have ranged from $1.06 to $11.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.65%. Company’s average yearly earnings per share was noted 43.74% at the time writing. With a float of $56.67 million, this company’s outstanding shares have now reached $60.47 million.
The extent of productivity of a business whose workforce counts for 145 workers is very important to gauge. In terms of profitability, gross margin is 76.78%, operating margin of -354.44%, and the pretax margin is -312.52%.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of C4 Therapeutics Inc is 17.39%, while institutional ownership is 83.23%. The most recent insider transaction that took place on Oct 18 ’24, was worth 83,321. Before that another transaction happened on Oct 11 ’24, when Company’s Director proposed sale 8,561 for $5.38, making the entire transaction worth $46,061.
C4 Therapeutics Inc (CCCC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 43.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Check out the current performance indicators for C4 Therapeutics Inc (CCCC). In the past quarter, the stock posted a quick ratio of 6.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.53 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
The latest stats from [C4 Therapeutics Inc, CCCC] show that its last 5-days average volume of 1.03 million was inferior to 2.13 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 25.21%. Additionally, its Average True Range was 0.48.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 1.76%, which indicates a significant decrease from 2.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.08% in the past 14 days, which was higher than the 86.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.89, while its 200-day Moving Average is $6.45. Now, the first resistance to watch is $4.74. This is followed by the second major resistance level at $5.18. The third major resistance level sits at $5.42. If the price goes on to break the first support level at $4.06, it is likely to go to the next support level at $3.82. The third support level lies at $3.38 if the price breaches the second support level.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are currently 70,589K shares outstanding in the company with a market cap of 277.81 million. Presently, the company’s annual sales total 20,760 K according to its annual income of -132,490 K. Last quarter, the company’s sales amounted to 15,360 K and its income totaled -24,670 K.
